Hypomagnesemia is having a serum magnesium concentration of <1.3 mEq/L.
Patients with mild hypomagnesemia is asymptomatic and have usually a serum Mg >0.5 mmol/L. While those with moderate-severe hypomagnesemia, the patient is symptomatic and have serum Mg <5 mmol/L.
Hypermagnesemia signs and symptoms usually do not appear unless Mg >2 mmol/L (5 mg/dL). It rarely occurs and usually iatrogenic.
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
New drug applications approved by US FDA as of 15-30 Aug which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.